Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Bladder Cancer
•
Medical Oncology
How do you manage dysgeusia from Enfortumab Vedotin?
Related Questions
What is your preferred approach for neoadjuvant treatment for muscle invasive bladder cancer, have you switched to durvalumab plus gemcitabine cisplatin over dose dense or accelerated MVAC?
Is there a clinical benefit for a repeat TURBT to ensure complete resection of the bladder tumor prior to neoadjuvant chemotherapy and radical cystectomy?
Do you offer neoadjuvant chemotherapy to nested variant urothelial carcinoma (NVUC) of the bladder?
Would you give any adjuvant therapy (chemo, immunotherapy and/or radiation) to a patient with pure small cell cancer of the urinary bladder who received neoadjuvant cisplatin and etoposide but had pN+ and residual invasive disease on cystectomy?
Under what circumstances would it be appropriate to offer trimodality therapy (TMT) in muscle-invasive bladder cancer with localized variant histology?
Would you consider neoadjuvant immunotherapy in a patient with Lynch syndrome and urothelial cancer?
Based on the results of the BladderPath trial, are you considering multiparametric bladder MRI for all patients with suspected bladder cancer diagnosis prior to TURBT, or for select patients only?
Are patients with MIBC and bladder neck involvement good candidates for bladder preservation with chemoradiation after maximal, but not complete, TURBT?
In patients with localized small cell bladder cancer, would you consider consolidation with durvalumab after neoadjuvant chemotherapy followed by definitive local therapy (cystectomy or RT)?
How would you approach adjuvant therapy in MIBC with predominantly squamous cell differentiation?
